Urothelial Cancer | Specialty

FDA Approval Sought for UGN-102 in Low-Grade, Intermediate-Risk NMIBC

August 14th 2024

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.

Dr Li on the Rationale for a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC

August 13th 2024

Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.

China’s NMPA Grants Breakthrough Therapy Designation to 9MW2821 in Advanced Urothelial Cancer

August 12th 2024

The Nectin-4–directed antibody-drug conjugate 9MW2821 has received breakthrough therapy designation in China for pretreated, advanced urothelial carcinoma.

Enfortumab Vedotin/Pembrolizumab Does Not Negatively Impact QOL in Metastatic Urothelial Cancer

August 9th 2024

Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

August 8th 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Park and Grivas Expand on Treatment Updates in Bladder Cancer

August 7th 2024

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Association Between Clonal Hematopoiesis, RCC, and Cardiovascular Disease

August 5th 2024

Valisha Shah, MS, discusses the observed association between clonal hematopoiesis and RCC with cardiovascular diseases.

Bladder-Sparing Treatment Post–Pembrolizumab Progression Is Effective in BCG-Unresponsive NMIBC

August 2nd 2024

Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.

Dr Msaouel on Ongoing Research With Bispecific Antibodies in RMC and Epithelioid Sarcoma

July 31st 2024

First-Line Avelumab Maintenance Extends OS in Advanced Urothelial Carcinoma With Low Tumor Burden

July 30th 2024

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

Dr Nawfal on Radiological Tumor Burden as an Independent Prognostic Factor of Survival in mccRCC

July 30th 2024

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.

Pembrolizumab Plus Enfortumab Vedotin Earns CHMP Recommendation in Frontline Metastatic Urothelial Carcinoma

July 26th 2024

The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in Metastatic RCC

July 25th 2024

Renee Saliby, MD, MSc discusses the relationship between intermediate end points and overall survival in metastatic renal cell carcinoma.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma. 

Dr Li on Unmet Needs in High-Risk MIBC

July 23rd 2024

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Dr Cigliola on the Background of the SURE-01 Study in MIBC

July 17th 2024

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions

July 15th 2024

IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions.

Dr Garje on the Benefits of Multimodal Treatment in Small Cell Bladder Cancer

July 15th 2024

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCC

July 10th 2024

Brian I. Rini, MD, FASCO, on findings from a biomarker analysis of the KEYNOTE-426 trial of pembrolizumab/axitinib vs sunitinib in renal cell carcinoma.

Neoadjuvant Sacituzumab Govitecan Data Draw Curiosity in Cisplatin-Ineligible MIBC

July 9th 2024

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.